Advisory Services

We offer four science-driven core competencies through our tailored biotech advisory services—each designed to drive growth and maximize value:

Competitive Intelligence & Portfolio Optimization

Assess market landscapes, therapeutic trends, and competitive positioning to inform prioritization and portfolio decisions

Corporate & Business Development

Lead licensing, partnerships, M&A, and strategic alliances to drive growth and maximize platform or pipeline value. Source, structure, and negotiate transactions, managing the full deal lifecycle from diligence through integration.

Integrated Business Strategy Leveraging Financial and Clinical Analytics

Conduct rigorous financial modeling—including NPV, DCF, cap table management, cash flow waterfalls, and valuation frameworks—to support investment and deal decisions. Apply advanced clinical analytics such as pharmacokinetic analysis, clinical trial evaluation, data benchmarking, and responder analysis. Together, these tools enable the delivery of data-driven strategies that optimize resource allocation and maximize value creation

Scientifically Driven Investor Relations

Shape messaging and strategy for corporate presentations, investor targeting, and engagement with the buy- and sell-side communities.

Our clients’ success stories speak volumes about the impact of our tailored advisory and consultancy services

“Rakesh stood out for his sharp analytical thinking and deep understanding of both the science and the market. His perspective consistently helped us see around corners and refine our messaging in ways that truly resonated with investors.”

VP Investor Relations

Private Immunology Company

“Rakesh brings a rare combination of scientific depth and investment acumen. His ability to quickly grasp complex data and translate it into actionable strategic insights made him an invaluable thought partner throughout our fundraising and clinical planning efforts.”

Chief Business Officer

Public Ph2 Rare Disease Company

“Rakesh’s insights were consistently ahead of the curve. His grasp of the competitive landscape and investor mindset helped us sharpen our narrative and build credibility with the right stakeholders at a critical time for our company.”